Raiffeisen Bank International AG Purchases 231,628 Shares of Hologic, Inc. $HOLX

Raiffeisen Bank International AG grew its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 33,863.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 232,312 shares of the medical equipment provider’s stock after purchasing an additional 231,628 shares during the quarter. Raiffeisen Bank International AG owned approximately 0.10% of Hologic worth $15,600,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Winnow Wealth LLC bought a new stake in Hologic in the third quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 273 shares during the last quarter. Root Financial Partners LLC purchased a new position in Hologic during the 3rd quarter valued at about $27,000. SJS Investment Consulting Inc. raised its position in Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 362 shares during the last quarter. Finally, Loomis Sayles & Co. L P purchased a new stake in Hologic in the 2nd quarter worth approximately $33,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on HOLX shares. Evercore downgraded shares of Hologic from an “outperform” rating to an “in-line” rating and reduced their price objective for the company from $79.00 to $78.00 in a research report on Monday, January 5th. Morgan Stanley boosted their price target on shares of Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 11th. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Two equities research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Hologic presently has a consensus rating of “Hold” and an average price target of $78.42.

Hologic Trading Up 0.4%

NASDAQ HOLX opened at $75.43 on Friday. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $75.47. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48. The stock’s fifty day moving average price is $74.92 and its 200-day moving average price is $71.85. The stock has a market cap of $16.84 billion, a P/E ratio of 31.43, a P/E/G ratio of 2.24 and a beta of 0.72.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The firm had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.The business’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.87 EPS. As a group, equities analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.